(Q42560079)

2 November 2017

Sorafenib induced tumor lysis syndrome in an advanced hepatocellular carcinoma patient (English)

1 reference

2 November 2017

1 reference

hepatocellular carcinoma

1 reference

1 reference

Wu-Shiung Huang

1

1 reference

2 November 2017

Chang-Hsu Yang

series ordinal

2

1 reference

2 November 2017

language of work or name

English

0 references

publication date

1 September 2009

1 reference

World Journal of Gastroenterology

2 November 2017

1 reference

2 November 2017

15

1 reference

2 November 2017

35

1 reference

2 November 2017

4464-4466

1 reference

Sorafenib in advanced hepatocellular carcinoma

2 November 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2747073

Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2747073

The management of tumor lysis syndrome.

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2747073

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2747073

Tumour lysis syndrome: new therapeutic strategies and classification

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2747073

Pathophysiology, clinical consequences, and treatment of tumor lysis syndrome

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2747073

Management of tumor lysis syndrome: prevention and treatment.

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2747073

Phase II study of sorafenib in patients with advanced hepatocellular carcinoma

28 May 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19764104

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Management of tumor lysis syndrome with standard continuous arteriovenous hemodialysis: case report and a review of the literature

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19764104

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.3748/WJG.15.4464

1 reference

2 November 2017

1 reference

2 November 2017

PubMed publication ID

19764104

1 reference